elranatamab will enhance the amount or outcome of ergotamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Elranatamab causes cytokine release syndrome (CRS) which could suppress action of CYP enzymes, resulting in improved exposure of CYP substrates.This table of contents is a navigational Software, proces… Read More